Jim Simons Albireo Pharma, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.01 - $23.78 $900,500 - $1.19 Million	-50,000 Reduced 35.8%	89,683 $1.94 Million
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $1.96 Million - $3.17 Million	120,183 Added 616.32%	139,683 $2.7 Million
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $183,546 - $369,171	9,900 Added 103.13%	19,500 $387,000
Q1 2022 May 13, 2022	BUY	$23.94 - $33.74 $229,824 - $323,904	9,600 New	9,600 $286,000
Q3 2019 Nov 13, 2019	SELL	$20.0 - $31.88 $204,960 - $326,706	-10,248 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$30.67 - $37.86 $435,514 - $537,612	-14,200 Reduced 58.08%	10,248 $330,000
Q1 2019 May 14, 2019	SELL	$22.22 - $32.21 $295,170 - $427,877	-13,284 Reduced 35.21%	24,448 $787,000
Q4 2018 Feb 13, 2019	BUY	$20.9 - $32.57 $788,598 - $1.23 Million	37,732 New	37,732 $926,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.